

## First Trust NYSE Arca Biotechnology ETF

### Fund Facts

Ticker	FBT
Cusip	33742D105
Exchange	TSX
Inception Date	30/10/2014
Management Fee	0.15%*
Management Expense Ratio	0.73% <sup>1</sup>
Distribution Frequency	Quarterly
Benchmark	NYSE® Arca® Biotechnology Index
Distribution Rate:	n.a. <sup>2</sup>
Total Net Asset Value	\$1,784,697

### Portfolio Characteristics of the Underlying Fund

Maximum Market Cap.	\$241,660
Median Market Cap.	\$26,751
Minimum Market Cap.	\$3,092
Price/Earnings	24.45
Price/Book	3.64
Price/Cash Flow	21.04
Price/Sales	4.76

### Top Geographic Exposure of the Underlying Fund

	% of NAV**
United States	82.43%
Switzerland	6.03%
The Netherlands	3.12%
Denmark	2.86%
Germany	2.76%
Ireland	2.65%

### Investment Objective

First Trust NYSE Arca Biotechnology ETF (the "First Trust ETF") seeks to replicate, to the extent possible, the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE® Arca® Biotechnology Index. The First Trust ETF provides exposure to its new index by investing all or substantially all of its assets in an underlying U.S. index fund known as First Trust NYSE® Arca® Biotechnology Fund, which is managed by the First Trust ETF's portfolio advisor.


### Key Features of Underlying Fund

- Exposure to companies in the biotechnology industry
- Concentrated portfolio of securities
- All the benefits of an ETF including intraday trading, transparency and liquidity and low fees



### Risk rating

First Trust Portfolios Canada has rated the volatility of this ETF as **high**. This rating is based on how much the Underlying Fund returns have changed from year to year. It doesn't tell you how volatile the ETF will be in the future. The rating can change over time. An ETF with a low risk rating can still lose money.



For more information about the risk rating and specific risks that can affect the ETF's returns, see the Risk Factors section of the ETF's prospectus.

Annualized Performance	1-month	3-month	6-month	YTD	1-year	3-year	5-year	10-year	Since Inception
NAV	-5.39%	13.58%	28.94%	18.45%	18.45%	10.78%	6.19%	8.35%	7.52%

Effective February 17, 2021, the First Trust ETF changed its investment objectives to seek to replicate, to the extent possible, the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE® Arca Biotechnology Index. The First Trust ETF provides exposure to its new index by investing all or substantially all of its assets in an underlying U.S. index fund known as First Trust NYSE® Arca® Biotechnology Fund, which is managed by the First Trust ETF's portfolio advisor. If this change had been effective throughout the performance measurement period the performance of the First Trust ETF should have more closely replicated performance of the index.

<sup>1</sup> As of December 31, 2024 audited annual financial statements and MRFP.

<sup>2</sup> Distribution rate is calculated by dividing the most recent annualized distribution paid or declared by the Net Asset Value. Distribution rates may vary. The distributed amount may include return of capital (ROC) from time to time.

\*The First Trust ETF's management fee will also bear the management fee of the underlying fund (i.e. First Trust NYSE® Arca® Biotechnology Index Fund).

## First Trust NYSE Arca Biotechnology ETF

The First Trust ETF will obtain exposure to the Index by investing in the Underlying Fund, a US-listed index ETF which itself replicates or substantially replicates the Index.

### Top Industry Exposure of the Underlying Fund

	% of NAV**
Health Care	99.84%
Cash & Equivalents	0.15%

### Top 10 Holdings of the Underlying Fund

	% of NAV
Exact Sciences Corporation	5.15%
Illumina, Inc.	4.13%
Regeneron Pharmaceuticals, Inc.	4.04%
Krystal Biotech, Inc.	4.02%
Natera, Inc.	4.00%
Bruker Corporation	3.95%
ACADIA Pharmaceuticals Inc.	3.94%
Veracyte, Inc.	3.58%
Biogen Inc.	3.55%
Incyte Corporation	3.48%

*\*\*Percentage of net asset value may not equal 100%*

The NYSE® Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.

The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.

## About First Trust

First Trust Canada is the trustee, manager and promoter of the fund. First Trust Canada and its affiliates First Trust Advisors L.P. ("FTA"), portfolio advisor to the fund, an Ontario Securities Commission registered portfolio manager and U.S. Securities and Exchange Commission registered investment advisor, and First Trust Portfolios L.P. ("FTP"), a FINRA registered broker-dealer, are privately held companies that provide a variety of investment services. FTA has approximately US \$309.05 billion in total assets under supervision or management.

Commissions, management fees and expenses all may be associated with ETF investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compound total returns including changes in the unit value and reinvestment of all distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by the unitholder that would have reduced returns. ETFs are not guaranteed, their values change frequently and past performance may not be repeated.

NYSE and NYSE® Arca Biotechnology Index ("Index") are service/trademarks of ICE Data Indices, LLC or its affiliates ("IDI") and have been licensed for use by First Trust in connection with the Fund. The Fund is not sponsored, endorsed, sold or promoted by IDI and IDI makes no representations or warranties regarding the advisability of investing in the Fund or as to the result to be obtained by any person from use of the Index in connection with the trading of the Fund. IDI and its third party suppliers accept no liability in connection with use of the index or the Fund. See the prospectus for a full copy of the disclaimer.